A virtual Experts Knowledge share on the topic of “Appropriate selection of patients for combination immunotherapy in HCC: the now and the next” Chaired by Prof. Peter Galle, MD, PhD (Germany) and co-chaired by Prof. Sammy Saab, MD (USA) and Prof. Amit Singal, M.D., M.S (USA)
The educational objectives for the meeting are:
- To provide insights into the combination therapy for unresectable or advanced HCC patients, covering both approved therapies and those that are in clinical development.
- To define the HCC patient population who should benefit most from each available treatment option based on efficacy and safety profile.
- To provide guidance on treatment sequencing